A recent pre-clinical study shows that tigecycline combined with venetoclax promotes the primary response of MYC/BCL2 double-hit B cell lymphoma cells to rituximab-based chemoimmunotherapeutic regimens, also known as R-CHOP [81]. The gene discussed is MYC; the disease is B-cell non-Hodgkin lymphoma.